UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000026321
Receipt No. R000030232
Scientific Title A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study on Improvements in Glucose Metabolism by Daily Ingestion of Products Containing Pinitol
Date of disclosure of the study information 2017/02/27
Last modified on 2019/02/28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study on Improvements in Glucose Metabolism by Daily Ingestion of Products Containing Pinitol
Acronym Improvements in Glucose Metabolism by Daily Ingestion of Products Containing Pinitol
Scientific Title A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study on Improvements in Glucose Metabolism by Daily Ingestion of Products Containing Pinitol
Scientific Title:Acronym Improvements in Glucose Metabolism by Daily Ingestion of Products Containing Pinitol
Region
Japan

Condition
Condition Healthy adults
Classification by specialty
Not applicable Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To investigate the safety and usefulness of 12-weeks daily ingestion of products containing pinitol for improvements in glucose metabolism.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes HbA1c levels after 4, 8 and 12 weeks of ingestion and 4weeks after the end of ingestion.
Key secondary outcomes Fasting blood glucose, glycoalbumin, insulin and HOMA-IR

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification YES
Dynamic allocation NO
Institution consideration Institution is not considered as adjustment factor.
Blocking YES
Concealment No need to know

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Food
Interventions/Control_1 Ingestion of three capsules containing pinitol daily for 12 weeks.
Interventions/Control_2 Ingestion of three placebo capsules daily for 12 weeks.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
65 years-old >
Gender Male and Female
Key inclusion criteria 1. Subjects whose FBG is>=100mg/dl and <126mg/dl or HbA1c >=5.6% and <6.5%.
2. Subjects who have relatively high HOMA-IR levels (selected by the screening results).
3. Subjects who agree to participate in this study with a written informed consent.
Key exclusion criteria 1. Subjects who are under physician's advice, treatment and/or medication for diabetes.
2. Subjects whose HbA1c is >=6.5%
3. Subjects whose FBG is >=126 mg/dl.
4. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities.
5. Subjects with major surgical history relevant to digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc.
6. Subjects with unusually high and/or low blood pressure and/or abnormal hematological data.
7. Subjects with severe anemia.
8. Pre- or post-menopausal women complaining obvious physical changes.
9. Subjects who are at risk of having allergic reactions to drugs or foods based on especially leguminous plants including soybeans, and ice plants, yeasts, gelatin and milk.
10. Subjects who regularly take medicine, functional foods and/or supplements (containing dietary fiber such as indigestible dextrin, polyphenol, etc.) which would affect glucose metabolism.
11. Heavy smokers, alcohol addicts or subjects with the eating disordered lifestyle.
12. Subjects who donated either 400ml whole blood within 16 weeks (women) /12 weeks (men) or 200ml whole blood within 4 weeks or blood components within 2 weeks prior to the current study.
13. Pregnant or lactating women or women expect to be pregnant during this study.
14. Subjects who currently participate in other clinical trials or participated within the last 4 weeks prior to the current study.
15. Any other medical and/ or health reasons unfavorable to participation into the current study judged by the principal investigator.
Target sample size 64

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Prof. Jun NISHIHIRA, M.D., Ph.D.
Organization Hokkaido Information University
Division name Department of Medical Management and Informatics
Zip code
Address 59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan
TEL 011-385-4411
Email nishihira@do-johodai.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Dir. Prof. Jun NISHIHIRA, M.D., Ph.D.
Organization Hokkaido Information University
Division name Health Information Science Center
Zip code
Address 59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan
TEL 011-385-4430
Homepage URL
Email nishihira@do-johodai.ac.jp

Sponsor
Institute Hokkaido Information University
Institute
Department

Funding Source
Organization The Ethics Committee approves that the source of funding shall not be disclosed.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 北海道情報大学 保健センター(北海道)

Other administrative information
Date of disclosure of the study information
2017 Year 02 Month 27 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2016 Year 12 Month 21 Day
Date of IRB
Anticipated trial start date
2017 Year 02 Month 28 Day
Last follow-up date
2017 Year 07 Month 16 Day
Date of closure to data entry
2017 Year 08 Month 30 Day
Date trial data considered complete
2017 Year 09 Month 06 Day
Date analysis concluded
2017 Year 12 Month 20 Day

Other
Other related information

Management information
Registered date
2017 Year 02 Month 27 Day
Last modified on
2019 Year 02 Month 28 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030232

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.